Project Grant HT94252410862
Award Date
8/1/24
Completion Date
7/31/27
Dollars Obligated
$1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $483,548.00 Project Grant was awarded on August 1, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports "SINGLE-CELL STUDIES OF IMMUNE-MEDIATED INJURY AND IMMUNOREGULATION IN HUMAN VCA REJECTION" at Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts. The research funded by this grant aims to advance the understanding of...
The Defense Health Agency awarded a $499,998.00 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "Identifying Biomarkers of Human VCA Rejection to Enable Noninvasive Diagnostic Testing." This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports biomedical research initiatives aimed at improving health outcomes for military service members, veterans, and the broader public. The research project at Brigham &...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
This federal Project Grant award of $999,999.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports advanced biomedical research by Brigham & Women's Hospital, a prominent academic medical center and research institution, to investigate EBV signatures in relapsing and progressive forms of multiple sclerosis. The research project will be conducted over a period of approximately 3 years, from Aug 1, 2025 to...
This $172,374 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by Brigham & Women's Hospital, Inc. (a subsidiary of Partners Healthcare System) to investigate the role of fatty acid metabolism in chromophobe renal cell carcinoma. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing understanding of this type of kidney cancer. The...
This federal Project Grant award, valued at $654,273.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research to develop innovative variable ventilation approaches to reduce ventilator-induced lung injury in patients with acute respiratory distress syndrome (ARDS). The primary awardee is Brigham & Women's Hospital Inc., which is a prominent academic medical center and research institution in Boston,...
This Project Grant award from the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) in the amount of $793,572.00 is effective August 15, 2024 and runs through August 14, 2027. The award has been transferred from the General Hospital Corporation to Brigham and Women's Hospital Inc. in Boston, MA. The grant will fund a research project titled "A NOVEL TRANSLATIONAL MECHANISM UNDERLYING TSC PATHOPHYSIOLOGY". Brigham and Women's Hospital, a prominent...
The federal Project Grant award for $236,072 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research to evaluate the efficacy of novel B7-H3 antibodies in tuberous sclerosis complex (TSC). The awardee, Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, will conduct this biomedical research project over a 2-year period from August 1, 2024 to July 31, 2026. As a leading academic medical center, Brigham...